Substrate-dependent functional alterations of seven CYP2C9 variants found in Japanese subjects

Drug Metabolism and Disposition

Volumn 37, Issue 9, 2009, Pages 1895-1903

  Maekawa, Keiko ^a   Harakawa, Noriko ^a   Sugiyama, Emiko ^a   Tohkin, Masahiro ^a   Kim, Su Ryang ^a   Kaniwa, Nahoko ^a   Katori, Noriko ^a   Hasegawa, Ryuichi ^a   Yasuda, Kazuki ^b   Kamide, Kei ^c   Miyata, Toshiyuki ^d   Saito, Yoshiro ^a   Sawada, Jun Ichi ^a  

^a NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C9; DICLOFENAC; GLIMEPIRIDE; LOSARTAN;

ALLELE; ANIMAL CELL; ARTICLE; CATALYSIS; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG OXIDATION; ENZYME SUBSTRATE; GENETIC VARIABILITY; JAPANESE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; WILD TYPE;

ALLELES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BLOTTING, WESTERN; CYTOCHROME P-450 ENZYME SYSTEM; DICLOFENAC; DNA, COMPLEMENTARY; GENETIC VARIATION; HUMANS; HYPOGLYCEMIC AGENTS; INSECTS; JAPAN; KINETICS; LOSARTAN; MICROSOMES; RATS; RECOMBINANT PROTEINS; SUBSTRATE SPECIFICITY; SULFONYLUREA COMPOUNDS;

HEXAPODA;

EID: 70349104778     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.027003     Document Type: Article

References (36)

1. Bae JW, Kim HK, Kim JH, Yang SI, Kim MJ, Jang CG, Park YS, and Lee SY (2005) Allele and genotype frequencies of CYP2C9 in a Korean population. Br J Clin Pharmacol 60:418-422. (Pubitemid 41428473)
2. Blaisdell J, Jorge-Nebert LF, Coulter S, Ferguson SS, Lee SJ, Chanas B, Xi T, Mohrenweiser H, Ghanayem B, and Goldstein JA (2004) Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics 14:527-537. (Pubitemid 39106854)
3. Crespi CL and Miller VP (1997) The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. Pharmacogenetics 7:203-210. (Pubitemid 27290634)
4. Dickmann LJ, Rettie AE, Kneller MB, Kim RB, Wood AJ, Stein CM, Wilkinson GR, and Schwarz UI (2001) Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol Pharmacol 60:382-387.
5. Guo Y, Wang Y, Si D, Fawcett PJ, Zhong D, and Zhou H (2005a) Catalytic activities of human cytochrome P450 2C9*1, 2C9*3 and 2C9*13. Xenobiotica 35:853-861. (Pubitemid 41759171)
6. Guo Y, Zhang Y, Wang Y, Chen X, Si D, Zhong D, Fawcett JP, and Zhou H (2005b) Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in humans. Drug Metab Dispos 33:749-753. (Pubitemid 40686627)
7. Herman D, Dolzan V, and Ingelman-Sundberg M (2007) Characterization of the novel defective CYP2C9*24 allele. Drug Metab Dispos 35:831-834. (Pubitemid 46798612)
8. Holstein A, Plaschke A, Ptak M, Egberts EH, El-Din J, Brockmöller J, and Kirchheiner J (2005) Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. Br J Clin Pharmacol 60:103-106. (Pubitemid 40942788)
9. Ibeanu GC, Goldstein JA, Meyer U, Benhamou S, Bouchardy C, Dayer P, Ghanayem BI, and Blaisdell J (1998) Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. J Pharmacol Exp Ther 286:1490-1495. (Pubitemid 29135566)
10. Kirchheiner J and Brockmöller J (2005) Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 77:1-16. (Pubitemid 40089477)
11. Kobayashi M, Takagi M, Fukumoto K, Kato R, Tanaka K, and Ueno K (2008) The effect of bucolome, a CYP2C9 inhibitor, on the pharmacokinetics of losartan. Drug Metab Pharmacokinet 23:115-119.
12. Lee CR, Goldstein JA, and Pieper JA (2002) Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 12:251-263.
13. Maekawa K, Fukushima-Uesaka H, Tohkin M, Hasegawa R, Kajio H, Kuzuya N, Yasuda K, Kawamoto M, Kamatani N, Suzuki K, et al. (2006) Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese. Pharmacogenet Genomics 16:497-514. (Pubitemid 43922347)
14. Melet A, Assrir N, Jean P, Pilar Lopez-Garcia M, Marques-Soares C, Jaouen M, Dansette PM, Sari MA, and Mansuy D (2003) Substrate selectivity of human cytochrome P450 2C9: importance of residues 476, 365, and 114 in recognition of diclofenac and sulfaphenazole and in mechanism-based inactivation by tienilic acid. Arch Biochem Biophys 409:80-91. (Pubitemid 36042904)
15. Miners JO and Birkett DJ (1998) Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 45:525-538.
16. Niemi M, Cascorbi I, Timm R, Kroemer HK, Neuvonen PJ, and Kivistö KT (2002) Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin Pharmacol Ther 72:326-332. (Pubitemid 35052992)
17. Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239:2370-2378.
18. Phillips AH and Langdon RG (1962) Hepatic triphosphopyridine nucleotide-cytochrome c reductase: isolation, characterization, and kinetic studies. J Biol Chem 237:2652-2660.
19. Rettie AE and Jones JP (2005) Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics. Annu Rev Pharmacol Toxicol 45:477-494. (Pubitemid 40267790)
20. Ritter MA, Furtek CI, and Lo MW (1997) An improved method for the simultaneous determination of losartan and its major metabolite, EXP3174, in human plasma and urine by high-performance liquid chromatography with fluorescence detection. J Pharm Biomed Anal 15:1021-1029. (Pubitemid 27199552)
21. Schwarz UI (2003) Clinical relevance of genetic polymorphisms in the human CYP2C9 gene. Eur J Clin Invest 33 (Suppl 2):23-30. (Pubitemid 37424038)
22. Sekino K, Kubota T, Okada Y, Yamada Y, Yamamoto K, Horiuchi R, Kimura K, and Iga T (2003) Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects. Eur J Clin Pharmacol 59:589-592. (Pubitemid 37494525)
23. Shimamoto J, Ieiri I, Urae A, Kimura M, Irie S, Kubota T, Chiba K, Ishizaki T, Otsubo K, and Higuchi S (2000) Lack of differences in diclofenac (a substrate for CYP2C9) pharmacokinetics in healthy volunteers with respect to the single CYP2C9*3 allele. Eur J Clin Pharmacol 56:65-68. (Pubitemid 30317784)
24. Si D, Guo Y, Zhang Y, Yang L, Zhou H, and Zhong D (2004) Identification of a novel variant CYP2C9 allele in Chinese. Pharmacogenetics 14:465-469. (Pubitemid 38971236)
25. Suzuki K, Yanagawa T, Shibasaki T, Kaniwa N, Hasegawa R, and Tohkin M (2006) Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes. Diabetes Res Clin Pract 72:148-154.
26. Tai G, Farin F, Rieder MJ, Dreisbach AW, Veenstra DL, Verlinde CL, and Rettie AE (2005) In-vitro and in-vivo effects of the CYP2C9*11 polymorphism on warfarin metabolism and dose. Pharmacogenet Genomics 15:475-481. (Pubitemid 41017596)
27. Takanashi K, Tainaka H, Kobayashi K, Yasumori T, Hosakawa M, and Chiba K (2000) CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics 10:95-104.
28. Tracy TS, Hutzler JM, Haining RL, Rettie AE, Hummel MA, and Dickmann LJ (2002) Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the F114L active site mutation of CYP2C9: effect on atypical kinetic metabolism profiles. Drug Metab Dispos 30:385-390.
29. Wang R, Chen K, Wen SY, Li J, and Wang SQ (2005) Pharmacokinetics of glimepiride and cytochrome P450 2C9 genetic polymorphisms. Clin Pharmacol Ther 78:90-92. (Pubitemid 40956936)
30. Wei L, Locuson CW, and Tracy TS (2007) Polymorphic variants of CYP2C9: mechanisms involved in reduced catalytic activity. Mol Pharmacol 72:1280-1288. (Pubitemid 350012601)
31. Yamazaki H, Nakajima M, Nakamura M, Asahi S, Shimada N, Gillam EM, Guengerich FP, Shimada T, and Yokoi T (1999) Enhancement of cytochrome P-450 3A4 catalytic activities by cytochrome b5 in bacterial membranes. Drug Metab Dispos 27:999-1004. (Pubitemid 29409634)
32. Yasar U, Forslund-Bergengren C, Tybring G, Dorado P, Llerena A, Sjöqvist F, Eliasson E, and Dahl ML (2002) Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin Pharmacol Ther 71:89-98. (Pubitemid 34124042)
33. Yasar U, Tybring G, Hidestrand M, Oscarson M, Ingelman-Sundberg M, Dahl ML, and Eliasson E (2001) Role of CYP2C9 polymorphism in losartan oxidation. Drug Metab Dispos 29:1051-1056. (Pubitemid 32605922)
34. Yin T, Maekawa K, Kamide K, Saito Y, Hanada H, Miyashita K, Kokubo Y, Akaiwa Y, Otsubo R, Nagatsuka K, et al. (2008) Genetic variations of CYP2C9 in 724 Japanese individuals and their impact on the antihypertensive effects of losartan. Hypertens Res 31:1549-1557.
35. Zhao F, Loke C, Rankin SC, Guo JY, Lee HS, Wu TS, Tan T, Liu TC, Lu WL, Lim YT, et al. (2004) Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin Pharmacol Ther 76:210-219. (Pubitemid 39221795)
36. Zhou YH, Zheng QC, Li ZS, Zhang Y, Sun M, Sun CC, Si D, Cai L, Guo Y, and Zhou H (2006) On the human CYP2C9*13 variant activity reduction: a molecular dynamics simulation and docking study. Biochimie 88:1457-1465.